• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibrosis-Pipeline Review H2 2017

    Fibrosis-Pipeline Review H2 2017

    • Report Code ID: RW00011060467
    • Category Life Sciences
    • No. of Pages 122
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Fibrosis-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis-Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

    Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibrosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
    -The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Fibrosis-Overview 7
    Fibrosis-Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 17
    Fibrosis-Therapeutics Assessment 18
    Assessment by Target 18
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 24
    Assessment by Molecule Type 26
    Fibrosis-Companies Involved in Therapeutics Development 28
    Acceleron Pharma Inc 28
    Aelis Farma SAS 28
    Anima Biotech Ltd 28
    Bristol-Myers Squibb Company 29
    Cellmid Ltd 29
    Clementia Pharmaceuticals Inc 30
    Complexa Inc 30
    Confo Therapeutics 31
    EA Pharma Co Ltd 31
    Five Prime Therapeutics Inc 31
    Genfit SA 32
    GlycoMimetics Inc 32
    iBio Inc 33
    Inception Sciences Inc 33
    Isarna Therapeutics GmbH 34
    Kadmon Corp LLC 34
    Kalyra Pharmaceuticals Inc 34
    Morphic Therapeutic Inc 35
    Neumedicines Inc 35
    Novartis AG 36
    Palatin Technologies Inc 36
    Proximagen Ltd 37
    Redx Pharma Plc 37
    Ribomic Inc 37
    Scholar Rock Inc 38
    SciFluor Life Sciences LLC 38
    SK Chemicals Co Ltd 38
    Symic Biomedical Inc 39
    Fibrosis-Drug Profiles 40
    ACE-2798-Drug Profile 40
    AEF-0118-Drug Profile 41
    AK-002-Drug Profile 42
    Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis-Drug Profile 43
    CAB-101-Drug Profile 44
    CALY-001-Drug Profile 46
    CWHM-12-Drug Profile 47
    Drugs for Fibrosis-Drug Profile 48
    elafibranor-Drug Profile 49
    G-XXX-Drug Profile 57
    IB-DMD-Drug Profile 58
    IBIOCFB-03-Drug Profile 59
    ISTH-1106-Drug Profile 62
    KL-01045-Drug Profile 63
    Monoclonal Antibodies for Fibrosis-Drug Profile 64
    Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis-Drug Profile 65
    Monoclonal Antibody 2 for Fibrosis-Drug Profile 66
    Monoclonal Antibody for Fibrotic Scar-Drug Profile 67
    Monoclonal Antibody to Activate BMP7 for Fibrosis-Drug Profile 68
    NCE-401-Drug Profile 69
    Neumomir-Drug Profile 70
    NMIL-121-Drug Profile 71
    PAT-048-Drug Profile 75
    phenylbutyrate-Drug Profile 76
    PL-5028-Drug Profile 77
    PRI-724-Drug Profile 78
    Proteins for Central Nervous System Disorders and Fibrosis-Drug Profile 80
    RBM-003-Drug Profile 81
    RBM-007-Drug Profile 82
    SB-061-Drug Profile 83
    Small Molecule for Fibrosis-Drug Profile 85
    Small Molecule for Fibrosis-Drug Profile 86
    Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases-Drug Profile 87
    Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 88
    Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases-Drug Profile 89
    Small Molecule to Inhibit MicroRNA for Vascular Fibrosis-Drug Profile 90
    Small Molecule to Inhibit ROCK2 for Fibrotic Diseases-Drug Profile 91
    Small Molecules for Fibrosis-Drug Profile 92
    Small Molecules for Fibrosis-Drug Profile 93
    Small Molecules for Fibrosis-Drug Profile 94
    Small Molecules for Fibrosis-Drug Profile 95
    Small Molecules for Fibrosis-Drug Profile 96
    Small Molecules for Fibrosis and Inflammatory Diseases-Drug Profile 97
    Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 98
    Small Molecules to Agonize GPCR for Fibrosis-Drug Profile 99
    Small Molecules to Agonize RARG for Fibrosis-Drug Profile 100
    Small Molecules to Antagonize Integrin Alpha V for Fibrosis-Drug Profile 101
    Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease-Drug Profile 102
    Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology-Drug Profile 103
    SRI-31277-Drug Profile 104
    ST-2001-Drug Profile 105
    ST-2022-Drug Profile 106
    Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology-Drug Profile 107
    TTX-330-Drug Profile 108
    X-165-Drug Profile 109
    XOMA-089-Drug Profile 110
    Fibrosis-Dormant Projects 111
    Fibrosis-Product Development Milestones 114
    Featured News & Press Releases 114
    Appendix 117
    Methodology 117
    Coverage 117
    Secondary Research 117
    Primary Research 117
    Expert Panel Validation 117
    Contact Us 117
    Disclaimer 118

    List of Tables
    Number of Products under Development for Fibrosis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Fibrosis-Pipeline by Acceleron Pharma Inc, H2 2017
    Fibrosis-Pipeline by Aelis Farma SAS, H2 2017
    Fibrosis-Pipeline by Anima Biotech Ltd, H2 2017
    Fibrosis-Pipeline by Bristol-Myers Squibb Company, H2 2017
    Fibrosis-Pipeline by Cellmid Ltd, H2 2017
    Fibrosis-Pipeline by Clementia Pharmaceuticals Inc, H2 2017
    Fibrosis-Pipeline by Complexa Inc, H2 2017
    Fibrosis-Pipeline by Confo Therapeutics, H2 2017
    Fibrosis-Pipeline by EA Pharma Co Ltd, H2 2017
    Fibrosis-Pipeline by Five Prime Therapeutics Inc, H2 2017
    Fibrosis-Pipeline by Genfit SA, H2 2017
    Fibrosis-Pipeline by GlycoMimetics Inc, H2 2017
    Fibrosis-Pipeline by iBio Inc, H2 2017
    Fibrosis-Pipeline by Inception Sciences Inc, H2 2017
    Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2017
    Fibrosis-Pipeline by Kadmon Corp LLC, H2 2017
    Fibrosis-Pipeline by Kalyra Pharmaceuticals Inc, H2 2017
    Fibrosis-Pipeline by Morphic Therapeutic Inc, H2 2017
    Fibrosis-Pipeline by Neumedicines Inc, H2 2017
    Fibrosis-Pipeline by Novartis AG, H2 2017
    Fibrosis-Pipeline by Palatin Technologies Inc, H2 2017
    Fibrosis-Pipeline by Proximagen Ltd, H2 2017
    Fibrosis-Pipeline by Redx Pharma Plc, H2 2017
    Fibrosis-Pipeline by Ribomic Inc, H2 2017
    Fibrosis-Pipeline by Scholar Rock Inc, H2 2017
    Fibrosis-Pipeline by SciFluor Life Sciences LLC, H2 2017
    Fibrosis-Pipeline by SK Chemicals Co Ltd, H2 2017
    Fibrosis-Pipeline by Symic Biomedical Inc, H2 2017
    Fibrosis-Dormant Projects, H2 2017
    Fibrosis-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Fibrosis-Dormant Projects, H2 2017 (Contd..2), H2 2017

    List of Figures
    Number of Products under Development for Fibrosis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    Acceleron Pharma Inc
    Aelis Farma SAS
    Anima Biotech Ltd
    Bristol-Myers Squibb Company
    Cellmid Ltd
    Clementia Pharmaceuticals Inc
    Complexa Inc
    Confo Therapeutics
    EA Pharma Co Ltd
    Five Prime Therapeutics Inc
    Genfit SA
    GlycoMimetics Inc
    iBio Inc
    Inception Sciences Inc
    Isarna Therapeutics GmbH
    Kadmon Corp LLC
    Kalyra Pharmaceuticals Inc
    Morphic Therapeutic Inc
    Neumedicines Inc
    Novartis AG
    Palatin Technologies Inc
    Proximagen Ltd
    Redx Pharma Plc
    Ribomic Inc
    Scholar Rock Inc
    SciFluor Life Sciences LLC
    SK Chemicals Co Ltd
    Symic Biomedical Inc

    Request for Sample

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//fibrosis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments